Arun KP

Dr. Arun KP

orcid

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 July 2022 in The Journal of Clinical Pharmacology
Verified
Journal Article
Closed access
BPBhavatharini Pa
Bhavatharini Pa
SGShri Sanghavi G
Shri Sanghavi G
GTGrace Thomas
Grace Thomas
AKArun KP
Arun KP

5 October 2025 in Annals of Neurosciences
Verified
Journal Article
Open access
BSBhavatharini Sukumaran
Bhavatharini Sukumaran
ASAswathy V S
Aswathy V S
RXRinu Mary Xavier
Rinu Mary Xavier
KMKishor M
Kishor M
SKSelvaraj Krishnamurthi
Selvaraj Krishnamurthi
DMDeepalakshmi Mani
Deepalakshmi Mani
Background: Genetic polymorphisms significantly influence individual responses to antidepressant medications. Among these, variations in the cytochrome P450 enzyme CYP2C19 , particularly the *2 allele, are known to affect drug metabolism, with implications for both efficacy and safety. South Indian populations exhibit a relatively high prevalence of this polymorphism, yet data specific to psychiatric cohorts remain limited. Purpose: This study aimed to determine the prevalence of the CYP2C19*2 polymorphism among South Indian psychiatric patients and to classify the corresponding metaboliser phenotypes to inform precision prescribing strategies for psychotropic medications. Methods: A cross-sectional observational study was conducted involving 140 psychiatric patients of South Indian ancestry across two tertiary psychiatric centres. Genomic DNA was extracted from peripheral blood samples and genotyped for the CYP2C19*2 (681G>A) variant using TaqMan-based real-time PCR. Participants were categorised into metaboliser phenotypes based on CPIC guidelines: normal (*1/*1), intermediate (*1/*2) and poor (*2/*2) metabolisers. Genotype frequencies were assessed for Hardy–Weinberg equilibrium (HWE) and descriptive statistics were used to summarise allele and phenotype distributions. Results: The CYP2C19*2 allele frequency was 27.5%. Genotype distribution was as follows: *1/*1 in 55.7%, *1/*2 in 33.6% and *2/*2 in 10.7% of participants. Accordingly, 44.3% of patients were classified as non-normal metabolisers (NMs) (intermediate or poor). The genotype distribution did not deviate significantly from HWE ( p = .0614), indicating population stability. Conclusion: A substantial proportion of South Indian psychiatric patients exhibit reduced CYP2C19 enzyme activity due to the presence of the *2 allele. These findings highlight the clinical utility of pre-emptive pharmacogenetic testing to guide antidepressant selection and dosing in this population, supporting the implementation of precision psychiatry in routine mental health care.

1 January 2019 in Research Journal of Pharmacy and Technology
Verified
Journal Article
Closed access
MDM Deepalakshmi
M Deepalakshmi
VVVeena Viswanathan
Veena Viswanathan
LVLakshmi Viswam
Lakshmi Viswam
AKArun KP
Arun KP

3 February 2022 in Pharmacogenomics
Verified
Journal Article
Closed access
SASasidharan Pillai V Aswathy
Sasidharan Pillai V Aswathy
KCKotha Rohith Chandra
Kotha Rohith Chandra
PJPakkath Jyothikrishna
Pakkath Jyothikrishna
AKArun KP
Arun KP
Clopidogrel is a prodrug chiefly metabolized by the hepatic isoenzyme CYP2C19 to its active metabolite that inhibits the platelet aggregation. It has been proven in many populations that the geneti...

18 October 2022 in Journal of Pure and Applied Microbiology
Verified
Journal Article
Open access
KCKeerthana Chandrasekar
Keerthana Chandrasekar
TNT Navaswetha
T Navaswetha
HVHemalatha Vasudevan
Hemalatha Vasudevan
SKS. Naveen Kumar
S. Naveen Kumar
AKArun KP
Arun KP

1 September 2023 in Journal of Pharmacology and Pharmacotherapeutics
Verified
Journal Article
Open access
SMSirajudeen Mahaboob
Sirajudeen Mahaboob
GGG.N.K. Ganesh
G.N.K. Ganesh
AKArun KP
Arun KP
SRS.D. Rajendran
S.D. Rajendran
Warfarin is the most commonly prescribed anti-coagulant medication. Warfarin’s pharmacokinetics (PK) in its enantiomeric form have been reported to be highly variable. Five population pharmacokinetic model studies for warfarin were identified in this systematic review. This review summarized these studies and reported on various factors affecting warfarin PK. Most studies reported a one-compartment model with first-order absorption and elimination for both S-warfarin and R-warfarin. Warfarin disposition has been reported to be influenced by various factors, including gender, age, genetic variation, body surface area (BSA), concurrent drug, weight, and ethnicity. So, all of these factors must be considered when addressing this pharmacokinetic variability. These models should undergo an external evaluation to confirm their generalizability and to support model-informed dosing in clinical settings.